<DOC>
	<DOCNO>NCT00669617</DOCNO>
	<brief_summary>This study evaluate onset action indacaterol ( 150 300 µg ) compare placebo , salbutamol 200 µg salmeterol/fluticasone 50/500 µg</brief_summary>
	<brief_title>Study Determine Onset Action Indacaterol Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female adult age ≥40 year , sign Informed Consent Form prior initiation studyrelated procedure Patients diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) ( moderatetosevere classify GOLD Guidelines , 2006 ) : Smoking history least 20 pack year Postbronchodilator Forced Expiratory Volume 1 Second ( FEV1 ) &lt; 80 % ≥30 % predict normal value . Postbronchodilator FEV1/Forced Vital Capacity ( FVC ) &lt; 70 % , FVC force vital capacity ( 'Post ' refers 1530 minute inhalation 400 μg salbutamol Visit 2 ) Pregnant / nurse woman woman childbearing potential Long term oxygen therapy ( 15 hour per day ) daily basis chronic hypoxemia Patients hospitalize COPD exacerbation 6 week prior Visit 2 Visit 3 Respiratory tract infection within 6 week prior Visit 2 Visit 3 Concomitant pulmonary disease , pulmonary tuberculosis ( unless chest xray confirms longer active ) clinically significant bronchiectasis Any history asthma , include : blood eosinophil count &gt; 400/mm3 ; onset asthma symptom prior age 40 year History long QT syndrome whose QTc ( Bazett 's ) measure Visit 2 Visit 3 prolong ( &gt; 450ms male &gt; 470ms female ) Clinically relevant lab abnormality / condition ( limit ) unstable ischemic heart disease , arrhythmia ( exclude stable AF ) , uncontrolled hypertension , uncontrolled hypo hyperthyroidism , hypokalemia , hyperadrenergic state condition investigator 's opinion might compromise patient safety compliance , interfere evaluation , preclude completion study Uncontrolled Type I / Type II Diabetes blood glucose outside normal HbA1c &gt; 8.0 % total hemoglobin measure Visit 2 Any patient lung cancer active cancer history cancer le 5 year diseasefree survival time History hypersensitivity study drug Irregular day/night , waking/sleeping cycle e.g . shift worker Live attenuate vaccination within 30 day prior Visit 2 Investigational drug within 30 day prior Visit 2 Known history noncompliance able use device perform spirometry Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>adult</keyword>
</DOC>